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Purpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor 
(VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial 
detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to 
age-related macular degeneration (AMD).
Methods: Prospective, comparative, nonrandomized pilot study included patients with PED 
comprising 50% of total lesion in subfoveal location with visual acuity (VA) 20/40–20/400 
and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. 
Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 
1.25 mg. Follow-up occurred every 4–6 weeks for 6 months. Reinjection of initial medication 
occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) 
or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) 
and foveal thickness.
Results: At baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib 
versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 µm). Mean improve-
ments to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; 
foveal thickness: −88.2 vs −52.9 µm). On average, pegaptanib-treated patients had slower but 
more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed 
rapid improvement with a slow return towards baseline. Both agents were well tolerated.
Conclusion: Intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe 
treatments for PED associated with occult CNV secondary to AMD.
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Introduction
Retinal pigment epithelial detachment (PED), in which the retinal pigment epithelium 
(RPE) physically separates from the underlying Bruch’s membrane, occurs in associa-
tion with many diseases of the retina, the most common being age-related macular 
degeneration (AMD).1 In patients with AMD, PEDs are classified by clinical appear-
ance and angiographic characteristics as confluent drusen, serous, turbid, hemorrhagic, 
vascular or fibrovascular, and fibrous or organized.2–5 The underlying pathophysiology 
of PED is complex and not clearly understood. Several contributing mechanisms have 
been proposed, the most obvious being displacement of the RPE by exudation from 
choroidal neovascularization (CNV). Because CNV is not always identified in patients 
with PED, however, controversy exists as to whether CNV develops as a complication 
of existing PED6 or whether the growth of CNV vessels through Bruch’s membrane 
directly causes PED.5 Bird and Marshall7 suggested that PED results when Bruch’s Clinical Ophthalmology 2010:4 370
Arias Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
membrane is thickened from the progressive accumulation 
of lipid or lipoprotein deposits, leading to increased hydro-
phobic resistance to the normal active transport of fluid 
and resulting in fluid accumulation beneath the RPE. These 
hypotheses concerning the pathogenesis of PED are believed 
not to be mutually exclusive.8
The visual prognosis for patients with CNV-associated 
PED may be especially poor. In a study that followed 55 eyes 
of 53 patients for an average of 2.2 years, 62% of patients 
were reported to have lost 6 or more lines of vision, with 75% 
having a final visual acuity of 20/200 or worse.9 Elman et al10 
reported in a retrospective analysis of the natural history of 
PED in patients without CNV that 52% of patients maintained 
an initial visual acuity of 20/20–20/40 through an average of 
32.8 months.10 Another study involving 101 eyes reported 
a similar course of vision loss irrespective of PED type.11 
Although patients without CNV may have a better prognosis 
at the onset, they are at high risk of developing CNV and sub-
sequent vision loss. In the Elman et al study,10 32% of patients 
eventually developed CNV while in another series,12 67% of 
patients with serous PED developed CNV after a maximum 
of 19 months. Since serous PED may obscure the extent of 
any existent CNV , it should be noted that proper assessment 
of patients with sub-RPE fluid is often rendered difficult.1
The management of AMD patients with PED is contro-
versial due to the difficulty in determining the presence of 
associated CNV and the inability to reliably identify those 
patients with serous PED who are likely to develop CNV 
and experience severe vision loss. In addition, treatment 
options for PED are limited and usually of poor outcome. 
While one trial13 of angiographically directed laser pho-
tocoagulation involving 35 eyes reported stabilization or 
improvement of vision in 60%, other attempts14,15 with both 
unguided and guided photocoagulation reported much infe-
rior results, with treated eyes faring worse than untreated 
controls. Results of studies of photodynamic therapy (PDT) 
with verteporfin have also not been encouraging. Although 
patients with PED were not specifically studied in either the 
Treatment of Age-related Macular Degeneration with Pho-
todynamic Therapy (TAP) or Verteporfin in Photodynamic 
Therapy (VIP) trials,16,17 a recent study18 enrolling lesions 
of 2 months’ duration found that 60% of patients had 
improved or stabilized vision over a 16-month follow-up. 
In contrast, other groups19,20 have reported that PDT with 
verteporfin conferred little treatment benefit, even when 
combined with intravitreal triamcinolone acetonide.21 In 
these trials, treatment was also complicated by subretinal 
hemorrhage and RPE tears.
Based on the suboptimal treatment outcomes with laser and 
PDT with verteporfin there is a need for a therapeutic approach 
that improves the prognosis of PED secondary to AMD. One 
promising avenue involves agents that inactivate vascular 
endothelial growth factor (VEGF), the most potent known 
promoter of angiogenesis22 and vascular permeability23 both 
of which appear to play a role in the pathogenesis of PED. Two 
intravitreal VEGF antagonists indicated for the treatment of all 
angiographic subclasses of CNV are commercially available: 
pegaptanib, an RNA aptamer, which has high affinity and speci-
ficity for the 165 amino acid isoform of VEGF while sparing 
VEGF121,24,25 and ranibizumab, an Fab antibody fragment that 
inactivates all VEGF isoforms.26–28 In addition, bevacizumab, 
an antibody related to ranibizumab, which is indicated for 
intravenous treatment of cancer in combination with chemo-
therapeutic agents (see prescribing information at: http://www.
gene.com/gene/products/information/oncology/avastin/ insert.
jsp# indications) and which also inactivates all VEGF isoforms, 
has been used in off-label studies to treat neovascular AMD.29 
The present pilot study examined the effectiveness of pegap-
tanib and bevacizumab in the treatment of PED associated with 
occult CNV secondary to AMD. The results are encouraging 
and merit further study in an appropriately designed random-
ized clinical trial.
Methods
This prospective, comparative, nonrandomized pilot study 
included patients with PED comprising 50% of the total 
lesion in the subfoveal location. Eligible patients had visual 
acuity between 20/40 and 20/400, and lesions that either had 
not been treated previously or had been treated only with 
PDT with verteporfin. Visual acuity (Early Treatment Dia-
betic Retinopathy Study [ETDRS]), a complete ophthalmic 
examination, indocyanine green angiography, fluorescein 
angiography, and optical coherence tomography (OCT) were 
evaluated at baseline. Examinations were completed 5–7 days 
before the administration of the first intravitreal injection.
The first seven patients presenting with PED received 
intravitreal injections of commercially available pegaptanib 
sodium 0.3 mg (Macugen®; [OSI] Eyetech, Inc and Pfizer 
Inc, New York, USA). The following eight patients received 
intravitreal injections of bevacizumab 1.25 mg in 0.05 mL 
prepared in a sterile compounding environment by the 
pharmacy service of our hospital. Injection procedures were 
identical for both therapies and included use of povidone 
iodine 5%, a sterile drape and gloves, and an eyelid speculum. 
Follow-up visits for each patient occurred every 4 to 6 weeks 
for 6 months. Each visit included a complete ophthalmic Clinical Ophthalmology 2010:4 371
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examination, visual acuity assessment (ETDRS), and OCT. 
Reinjection of the initial medication occurred if there was 
evidence of intra- or subretinal fluid by OCT or an increase 
in RPE detachment.
Study endpoints were mean changes from baseline to 
month 6 in visual acuity (ETDRS and logMAR [logarithm 
of the minimum angle of resolution]), and in foveal thick-
ness (OCT).
Informed consent was obtained. All applicable insti-
tutional and governmental regulations concerning the 
ethical use of human volunteers were followed during this 
research.
Results
Characteristics of the 15 patients were similar across treat-
ment groups at baseline (Table 1); two patients who received 
pegaptanib and three who received bevacizumab had been 
treated previously with PDT with verteporfin. A mean of 3.7 
(range 3–4) and 3.4 (range 2–5) injections of pegaptanib and 
bevacizumab were administered, respectively.
At baseline, mean visual acuity was lower and foveal 
thickness was greater in the pegaptanib treated patients 
(Table 2). Improvements in visual acuity measured by 
both ETDRS and logMAR and reductions in foveal thick-
ness were seen in each treatment group between baseline 
and month 6, but functional and anatomical changes were 
greater for all outcomes among patients treated with pegap-
tanib. The pattern of improvement varied by treatment 
(Figure 1). On average, pegaptanib-treated patients had 
Table 1 Patient baseline characteristicsa
Characteristic  Pegaptanib  
0.3 mg N = 7
Bevacizumab  
1.25 mg N = 8
Mean age (years) 74.5 73.3
Gender
  Male 4 4
  Female 3 4
Treated eye
  Left 4 5
  Right 3 3
Phakic/pseudophakic
  Phakic 5 6
  Pseudophakic 2 2
Previous treatment
  None 5 5
  PDT with verteporfin 2 3
Note: aNumber of patients unless otherwise specified.
Abbreviation: PDT, photodynamic therapy.
Table 2 Changes from baseline to month 6 in visual acuity and 
foveal thickness by treatment group, mean ± standard deviation
Outcome  Pegaptanib  
0.3 mg N = 7
Bevacizumab  
1.25 mg N = 8
Visual acuity, ETDRS letters
Baseline 36.1 ± 14.9 49.5 ± 11.5
Month 6 45.2 ± 19.8 56.7 ± 10.5
  Change, baseline to month 6 +9.1 ± 25.3 +7.2 ± 12.3
Visual acuity, logMAR
Baseline 1.00 ± 0.31 0.72 ± 0.23
Month 6 0.80 ± 0.40 0.57 ± 0.21
  Change, baseline to  
month 6
−0.20 ± 0.49 −0.15 ± 0.26
Foveal thickness, µm
Baseline 470.4 ± 140.8 321.1 ± 77.3
Month 6 382.2 ± 99.4 268.2 ± 35.4
  Change, baseline to month 6 −88.2 ± 208.6 −52.9 ± 70.7
Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; logMAR,   
logarithm of the minimum angle of resolution.
65
60
55
50
45
40
35
30
25
500
A
B
450
M
e
a
n
 
f
o
v
e
a
l
 
t
h
i
c
k
n
e
s
s
(
µ
m
,
 
O
C
T
)
M
e
a
n
 
v
i
s
u
a
l
 
a
c
u
i
t
y
(
l
e
t
t
e
r
s
,
 
E
T
D
R
S
)
400
350
300
250
200
Baseline Month 1 Month 3 Month 6
Baseline Month 1 Month 3 Month 6
Pegaptanib (n = 7)
Bevacizumab (n = 8)
49
57
60 56
45
36
32
36
470
424
380
382
268
265
218
321
Pegaptanib (n = 7)
Bevacizumab (n = 8)
Figure 1 A) Mean visual acuity (VA; Early Treatment Diabetic Retinopathy Study 
[ETDRS] letters) at baseline and at months 1, 3 and 6 in eyes receiving pegaptanib 
or bevacizumab. B) Mean foveal thickness (µm) determined by optical coherence 
tomography (OCT) at baseline and at months 1, 3, and 6 in eyes receiving pegaptanib 
or bevacizumab.Clinical Ophthalmology 2010:4 372
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A
B
Basal: VA = 35 letters (20/200) Month 1: VA = 52 letters (20/100)
Month 6: VA = 70 letters (20/40) Month 3: VA = 53 letters (20/80)
C
Figure 2 A 75-year-old female patient with previously untreated advanced age-related 
macular degeneration in the right eye received pegaptanib every 6 weeks for 3 injec-
tions. A) Fundus photograph at baseline (left panel) and fluorescein angiography (right 
panel). B) Indocyanine green angiography at baseline and 6 months. C) Optical coher-
ence tomography images and visual acuity (VA; Early Treatment Diabetic Retinopathy 
Study [ETDRS] letters) at baseline and months 1, 3, and 6.
slower but more sustained improvement in visual acuity 
and foveal thickness while those treated with bevacizumab 
demonstrated rapid improvement with a diminished effect 
over time.
Both agents were safe and well tolerated; neither ocular 
nor systemic complications were observed in any patient.
Illustrative cases of eyes treated with pegaptanib (Fig-
ures 2 A–C and 3A, B) and bevacizumab (Figures 4A, B 
and 5A, B) are shown.
Basal: VA = 54 letters (20/80) Month 1: VA = 45 letters (20/125)
Month 6: VA = 42 letters (20/125) Month 3: VA = 44 letters (20/125)
B
A
Figure 3 A 76-year-old male patient having a disciform scar in the left eye and no prior 
treatments received 4 injections of pegaptanib. A) Fundus photograph at baseline (left 
panel) and fluorescein angiography (right panel). B) Optical coherence tomography 
images and visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] 
letters) at baseline and months 1, 3, and 6.
Basal: VA = 60 letters (20/63) Month 1: VA = 35 letters (20/200)
Month 6: VA = 55 letters (20/80) Month 3: VA = 45 letters (20/125)
B
A
Figure 4 An 80-year-old male patient with a disciform scar in the right eye received 
prior photodynamic therapy with verteporfin and 3 injections of bevacizumab. 
A) Fluorescein angiography. B) Optical coherence tomography images and visual 
acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) at baseline 
and months 1, 3, and 6.Clinical Ophthalmology 2010:4 373
Anti-angiogenic therapy for retinal PED Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Basal: VA = 34 letters (20/250) Month 1: VA = 59 letters (20/63)
Month 6: VA = 68 letters (20/40) Month 3: VA = 58 letters (20/80)
B
A
Figure 5 A 61-year-old female patient with a normal right eye having received no prior 
treatments was administered 4 injections of bevacizumab. A) Fundus photograph at 
baseline (left panel) and fluorescein angiography (right panel). B) Optical coherence 
tomography images and visual acuity (VA; Early Treatment Diabetic Retinopathy Study 
[ETDRS] letters) at baseline and months 1, 3, and 6.
Discussion
The principal finding in this pilot study is that both selective 
VEGF inhibition with pegaptanib and nonselective VEGF 
inhibition with bevacizumab provided similar anatomical and 
functional benefits in the treatment of PED, with no safety 
signals having emerged. These results are similar to those 
seen in another recent pilot study with bevacizumab, also 
directed against PED secondary to AMD.30 In the present 
report the two agents provided qualitatively similar benefits, 
while pegaptanib-treated patients showed somewhat greater 
improvements in terms of mean visual acuity and retinal 
thickness despite the overall poorer baseline condition. 
The difference in the number of injections administered 
between the treatment groups was less than 10%, suggest-
ing that undertreatment with bevacizumab was unlikely to 
be the cause. There also appeared to be a difference in the 
time courses of the responses to the two drugs, with patients 
receiving pegaptanib requiring a longer timeframe to achieve 
visual acuity improvements than bevacizumab, but one that 
was more sustained over the longer term. It is interesting 
that for both pegaptanib and bevacizumab the vision seemed 
to improve despite the fact that the PED size seems to have 
fluctuated over time.
While the data in the present study must be viewed as 
preliminary, they suggest that it may not be necessary to 
inhibit all VEGF isoforms for treatment of PED, in that 
selective inhibition of VEGF165 with pegaptanib produced 
comparable effects to bevacizumab. These findings are 
relevant to safety in that nonselective VEGF inhibition with 
ranibizumab was found be associated with a significantly 
higher incidence of nonocular hemorrhage compared to 
controls.31 In addition, early data from the Safety Assessment 
of Intravitreal Lucentis for AMD (SAILOR) trial examining 
ranibizumab safety has indicated a significantly increased 
risk of stroke for the 0.5 mg versus 0.3 mg dose, prompting a 
physician advisory letter from the manufacturer which can be 
found at: http://www.fda.gov/medwatch/safety/2007/Lucen-
tis_DHCP_01-24-2007.pdf. Whether these risks apply to 
bevacizumab, which is also a nonselective VEGF antagonist, 
is not known, since its use has not been evaluated in large, 
properly controlled trials.29
Another issue of concern is the risk of RPE tears, a recog-
nized complication of PED, in patients treated with anti-VEGF 
therapy. Chang and Sarraf 32 have analyzed reports of RPE tears 
for all three anti-VEGF agents in the treatment of AMD and 
found that a pre-existing PED was a common feature. Similar 
conclusions have been reached in other retrospective studies 
with bevacizumab.30,33,34 PED is a predisposing factor for RPE 
tears even in untreated patients, and it remains to be determined 
whether anti-VEGF therapy accelerates the natural history of 
these cases, or contributes an additional risk that may require 
other adjustments in treatment regimens.32
The main limitation of this study is that it enrolled only 
a small number of patients. Other limitations included a 
lack of randomization and the relatively short duration of 
follow-up. Therefore, these findings require confirmation in 
a larger randomized study, which could also answer questions 
regarding the optimal dose, long-term efficacy and safety, 
and criteria for retreatment.
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